TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE

Vikram Mathews, Ezhilarasi Chendamarai, Biju George, Auro Viswabandya, Alok Srivastava
  • Vikram Mathews
    Vikram Mathews Department of Haematology, Christian Medical College and Hospital, Vellore 632004 India. Telephone No: 91-416-2282891 Fax No: 91-416-2226449 E-mail vikram@cmcvellore.ac.in, India | vikram@cmcvellore.ac.in
  • Ezhilarasi Chendamarai
    Affiliation not present
  • Biju George
    Affiliation not present
  • Auro Viswabandya
    , ,,,
  • Alok Srivastava
    Affiliation not present

Abstract

It is well recognized that arsenic trioxide (ATO) is an efficacious agent for the treatment of acute promyelocytic leukemia (APL). Use of single agent ATO in the treatment of APL leads to remissions which are durable in the majority. ATO is probably the most effective single agent in the treatment of APL and there have been very few reports of primary resistance. It has been used both as a single agent and in combination with other conventional drugs to treat APL. Use of ATO is the accepted standard of care in the management of relapsed APL, where it is often used effectively as a bridge to a stem cell transplant. However, its role in newly diagnosed APL remains controversial. ATO probably has multiple mechanisms of action. Better understanding of its mechanisms of action/s is likely to lead to more rationale use of this agent or its derivatives either alone or in combination with other drugs. There is limited data on the kinetics of leukemia clearance and normal haematopoietic recovery after the administration of single agent ATO for the treatment of APL, preliminary data suggests that it is likely to be different from conventional therapy. There have been a number of concerns of the potential short and long term toxicity of this agent. Most such concerns arise from the toxicity profile noted in people exposed to long term arsenic exposure in the environment. With the therapeutic doses and schedules of administration of ATO in the treatment of malignancies the overall toxicity profile has been favorable. In a resource constrained environments the use of a single agent ATO based regimen is a realistic and acceptable option to treat almost all patients. In the developed world it has the potential in combination with other agents to improve the clinical outcome with reduction of dose intensity of chemotherapy and remains an option for patients who would not tolerate conventional therapy. In this review we focus on the use of single agent ATO for the treatment of APL and summarize our experience and review the literature.

Keywords

APL. ARSENIC TRIOXIDE, dEVELOPING COUNTRIES

Full Text:

PDF
HTML
Submitted: 2014-06-12 16:03:41
Published: 2011-11-28 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1876

Views:
PDF
158
HTML
3737

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Comments on this article

View all comments


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy